Compare Canadian Natural Resources Ltd. (CNQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian Natural Resources Ltd. vs Neurocrine Biosciences Inc — how do they compare? Canadian Natural Resources Ltd. trades at $47.69 (market cap $98.11B), while Neurocrine Biosciences Inc trades at $159.01 (market cap $16.46B). The key difference: Canadian Natural Resources Ltd. is far larger — about 6× Neurocrine Biosciences Inc's market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CNQ | NBIX | |
|---|---|---|
Market Cap | $98.11B | $16.46B |
Sector | Energy | Health |
52-Week High | $50.55 | $185.50 |
52-Week Low | $29.31 | $123.10 |
Enterprise Value | $108.54B | $16.48B |
Dividend Yield | 3.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CNQ trades at $47.25, up 3.82% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.53, exceeding expectations, and maintains robust profitability with a net income margin of 22.87%. Recent news highlights record production and a quarterly dividend of $0.63, reinforcing financial strength.
Outlook is positive due to low valuation multiples, consistent dividend payouts, and upward earnings revisions. Key risks include oil price volatility and rising debt levels. Analyst consensus is strongly bullish with 75% buy ratings, supporting potential upside if operational momentum continues.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
